[Follow-up evaluation of metastatic neuroblastoma using high dose [131I-meta]iodobenzylguanidine].
Between 1989 and 1990 nine children with neuroblastoma stage IV (according to Evans) have been treated with high-dose [131I-meta]Iodobenzylguanidine (HD-mIBG). The total HD-mIBG dose administered to each child was at mean 699.3 +/- 111 MBq/kg body weight. Prior to (median 28 days) and after (median 50 days) HD-mIBG treatment a diagnostic scan with [123I-meta]Iodobenzylguanidine ([123I-m]IBG) was performed. Scans performed with HD-mIBG were superior to diagnostic scans for the detection of bone lesions in 8/9 children, for the detection of soft tissue lesions in 4/9 children, and for a more precise diagnosis of the primary tumor in 1 child. In 4 children lesions which were primarily identified in the therapeutic scan could be further observed in posttherapeutical examinations.
Klingebiel
T
T
Kinderklinik II, Eberhard-Karls-Universität, Tübingen, FRG.
Reuland
P
P
Feine
U
U
Niethammer
D
D
D019797:3-Iodobenzylguanidine; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D006801:Humans; D007223:Infant; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000627:therapeutic use*; D008297:Male; D009447:Neuroblastoma / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000532:radiotherapy*; D011877:Radionuclide Imaging
D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine
Verlaufsbeurteilung des metastasierten Neuroblastoms mittels hochdosiertem [131J-meta]Jodobenzylguanidin.